Medical Devices - Surgical Robotics & Orthopedic Implants
Strategic Profile
The company's vision is to combine a surgical robot that addresses economic and clinical pain points with personalized implants, moving away from the generic "one size fits none" model that is too costly. A historic milestone was achieved with the world's first fully autonomous saw-based robotic knee replacement surgery on a live patient on July 26, 2025, at Krishna Shalby Hospital in Ahmedabad, India.
Cyborg Score Rationale
The company received FDA 510(k) clearance for its mBôs TKA System for total knee arthroplasty. Zimmer Biomet's acquisition at $4.04 per share represents approximately $177 million equity value. Strong technology validation with first autonomous robotic knee surgery completed and clinical trials underway.
Top Insights
World's first fully autonomous saw-based robotic knee replacement completed July 26, 2025, validating autonomous surgical technology
FDA 510(k) clearance for mBôs TKA System designed for enhanced safety, efficiency, and accuracy in knee replacement
Acquired by Zimmer Biomet at $4.04/share for ~$177M, providing distribution and market access through major medtech leader
102-patient multi-center clinical trial in India underway evaluating system safety and effectiveness with Consensus CKS implants
Named Competitors
Mako Surgical System — Robotic-assisted knee and hip replacement system
ROSA Knee System — Robotic-assisted knee arthroplasty platform
CORI Surgical System — AI-enabled robotic-assisted knee replacement
Recent Developments
(July 2025) Completed world's first autonomous saw-based robotic knee replacement surgery on live patient
(May 2025) Received FDA 510(k) clearance for mBôs TKA System for total knee arthroplasty
(October 2025) Acquisition by Zimmer Biomet completed at $4.04 per share
Open the full interactive Monogram Technologies Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.